Clinical trial · Interventional
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
A Phase II Trial of Celecoxib in Patients With IPMN
NCT00198081CI-TRIAL-00021180terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of funding and personnel to conduct study.
Summary
Brief summary (as posted)
The purpose of the study is to find out whether the drug celecoxib has beneficial effects on people with pre-cancerous lesions of the pancreas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Neoplasms | Pancreatic Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| COX-2 Inhibitor 6-8 weeks prior to surgery | Drug | — | UNRESOLVED |
| COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Surgical Candidate
- description
- COX-2 Inhibitor 6-8 weeks prior to surgery
- interventionNames
- Drug: COX-2 Inhibitor 6-8 weeks prior to surgery
- type
- EXPERIMENTAL
- label
- Medical Candidate
- description
- COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
- interventionNames
- Drug: COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
Primary outcomes (4)
- measure
- Concentration of PGE2 in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 Months
- timeFrame
- Baseline, surgery, 1 wk, 4 wks, and 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of IPMN * ECOG Performance status of 0, 1, or 2 * Adequate liver function, bilirubin \< 1.5 times ULN, ALT or AST \< 2.5 times ULN * Adequate renal function: creatinine \< 1.8 * Must be at least 18 Exclusion Criteria: * Use of COX-2 selective inhibitors within the last month * More than occasional use of NSAIDS in last month (occasional use defined as up to twice weekly dosing) * CA19-9 levels 1.5 times the ULN * Active pancreatitis * Taking sulphonylureas, fluconazole or lithium concomitantly
References
Publications (0)
Data not yet available
No reference posted for this study.